Patents and Innovation in Cancer Therapeutics

Lessons from CellPro

Avital Bar-Shalom, Robert Cook-Deegan

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

This article discusses the interaction between intellectual property and cancer treatment. CellPro developed a stem cell separation technology based on research at the Fred Hutchinson Cancer Center. A patent with broad claims to bone marrow stem cell antibodies had been awarded to Johns Hopkins University and licensed to Baxter Healthcare under the 1980 Bayh-Dole Act to promote commercial use of inventions from federally funded research. CellPro got FDA approval more than two years before Baxter but lost patent infringement litigation. NIH elected not to compel Hopkins to license its patents to CellPro. CellPro went out of business, selling its technology to its competitor. Decisions at both firms and university licensing offices, and policies at the Patent and Trademark Office, NIH, and the courts influenced the outcome.

Original languageEnglish (US)
Pages (from-to)637-676
Number of pages40
JournalMilbank Quarterly
Volume80
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Patents
Licensure
patent
cancer
Stem Cells
Intellectual Property
innovation
Technology
Cell Separation
Jurisprudence
Research
Bone Marrow Cells
Neoplasms
Delivery of Health Care
trademark
Antibodies
intellectual property
Therapeutics
selling
invention

ASJC Scopus subject areas

  • Health Policy
  • Nursing(all)
  • Health(social science)
  • Health Professions(all)

Cite this

Patents and Innovation in Cancer Therapeutics : Lessons from CellPro. / Bar-Shalom, Avital; Cook-Deegan, Robert.

In: Milbank Quarterly, Vol. 80, No. 4, 2002, p. 637-676.

Research output: Contribution to journalArticle

@article{2575c8d318ad4394a3c09e066a3a2d02,
title = "Patents and Innovation in Cancer Therapeutics: Lessons from CellPro",
abstract = "This article discusses the interaction between intellectual property and cancer treatment. CellPro developed a stem cell separation technology based on research at the Fred Hutchinson Cancer Center. A patent with broad claims to bone marrow stem cell antibodies had been awarded to Johns Hopkins University and licensed to Baxter Healthcare under the 1980 Bayh-Dole Act to promote commercial use of inventions from federally funded research. CellPro got FDA approval more than two years before Baxter but lost patent infringement litigation. NIH elected not to compel Hopkins to license its patents to CellPro. CellPro went out of business, selling its technology to its competitor. Decisions at both firms and university licensing offices, and policies at the Patent and Trademark Office, NIH, and the courts influenced the outcome.",
author = "Avital Bar-Shalom and Robert Cook-Deegan",
year = "2002",
doi = "10.1111/1468-0009.00027",
language = "English (US)",
volume = "80",
pages = "637--676",
journal = "Milbank Quarterly",
issn = "0887-378X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Patents and Innovation in Cancer Therapeutics

T2 - Lessons from CellPro

AU - Bar-Shalom, Avital

AU - Cook-Deegan, Robert

PY - 2002

Y1 - 2002

N2 - This article discusses the interaction between intellectual property and cancer treatment. CellPro developed a stem cell separation technology based on research at the Fred Hutchinson Cancer Center. A patent with broad claims to bone marrow stem cell antibodies had been awarded to Johns Hopkins University and licensed to Baxter Healthcare under the 1980 Bayh-Dole Act to promote commercial use of inventions from federally funded research. CellPro got FDA approval more than two years before Baxter but lost patent infringement litigation. NIH elected not to compel Hopkins to license its patents to CellPro. CellPro went out of business, selling its technology to its competitor. Decisions at both firms and university licensing offices, and policies at the Patent and Trademark Office, NIH, and the courts influenced the outcome.

AB - This article discusses the interaction between intellectual property and cancer treatment. CellPro developed a stem cell separation technology based on research at the Fred Hutchinson Cancer Center. A patent with broad claims to bone marrow stem cell antibodies had been awarded to Johns Hopkins University and licensed to Baxter Healthcare under the 1980 Bayh-Dole Act to promote commercial use of inventions from federally funded research. CellPro got FDA approval more than two years before Baxter but lost patent infringement litigation. NIH elected not to compel Hopkins to license its patents to CellPro. CellPro went out of business, selling its technology to its competitor. Decisions at both firms and university licensing offices, and policies at the Patent and Trademark Office, NIH, and the courts influenced the outcome.

UR - http://www.scopus.com/inward/record.url?scp=0041413137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041413137&partnerID=8YFLogxK

U2 - 10.1111/1468-0009.00027

DO - 10.1111/1468-0009.00027

M3 - Article

VL - 80

SP - 637

EP - 676

JO - Milbank Quarterly

JF - Milbank Quarterly

SN - 0887-378X

IS - 4

ER -